The Philadelphia Prostate Cancer Consensus Conference guidelines 2019 state that men with metastatic PCa should have germline testing in BRC2/BRCA1, DNA MMR genes (recommended) while ATM gene testing should be considered. This evidence concerns the gene BRCA1 and prostate carcinoma.